DK0559884T4 - Rekombinante virusvektorer til ekspression i muskelceller - Google Patents

Rekombinante virusvektorer til ekspression i muskelceller

Info

Publication number
DK0559884T4
DK0559884T4 DK92921684T DK92921684T DK0559884T4 DK 0559884 T4 DK0559884 T4 DK 0559884T4 DK 92921684 T DK92921684 T DK 92921684T DK 92921684 T DK92921684 T DK 92921684T DK 0559884 T4 DK0559884 T4 DK 0559884T4
Authority
DK
Denmark
Prior art keywords
muscle cells
expression
vectors
viral vectors
recombinant viral
Prior art date
Application number
DK92921684T
Other languages
Danish (da)
English (en)
Other versions
DK0559884T3 (da
Inventor
Michel Perricaudet
Pascale Briand
Leslie Stratford-Perricaudet
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9417378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0559884(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK0559884T3 publication Critical patent/DK0559884T3/da
Publication of DK0559884T4 publication Critical patent/DK0559884T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK92921684T 1991-09-27 1992-09-25 Rekombinante virusvektorer til ekspression i muskelceller DK0559884T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9111947A FR2681786A1 (fr) 1991-09-27 1991-09-27 Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
PCT/FR1992/000898 WO1993006223A1 (fr) 1991-09-27 1992-09-25 Vecteurs recombinants viraux pour l'expression dans des cellules musculaires

Publications (2)

Publication Number Publication Date
DK0559884T3 DK0559884T3 (da) 2000-10-02
DK0559884T4 true DK0559884T4 (da) 2004-08-02

Family

ID=9417378

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92921684T DK0559884T4 (da) 1991-09-27 1992-09-25 Rekombinante virusvektorer til ekspression i muskelceller

Country Status (12)

Country Link
EP (1) EP0559884B2 (enExample)
JP (1) JP3487597B2 (enExample)
AT (1) ATE192500T1 (enExample)
AU (1) AU666142B2 (enExample)
CA (1) CA2097185C (enExample)
DE (1) DE69230993T3 (enExample)
DK (1) DK0559884T4 (enExample)
ES (1) ES2147553T5 (enExample)
FR (1) FR2681786A1 (enExample)
GR (1) GR3034094T3 (enExample)
SG (1) SG49081A1 (enExample)
WO (1) WO1993006223A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
AU5457294A (en) * 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
ATE307212T1 (de) * 1992-11-18 2005-11-15 Arch Dev Corp Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
FR2718749B1 (fr) * 1994-04-18 1996-05-31 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
BR9405507A (pt) * 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US6673601B1 (en) 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1721982B1 (en) 1999-04-15 2013-04-10 Boehringer Ingelheim Vetmedica GmbH Chimeric lyssavirus nucleic acids and polypeptides
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
US7238672B1 (en) 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
CN1526014A (zh) * 2000-10-06 2004-09-01 ��ʽ���������о��� 用于将外源基因导入骨骼肌的副粘病毒载体
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
AU2005294265A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
CA2595407A1 (en) 2005-01-20 2006-07-27 University Of Rochester Thioredoxin interacting protein (txnip) as regulator of vascular function
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
WO2012092341A1 (en) 2010-12-28 2012-07-05 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
CA1339346C (en) * 1986-08-01 1997-08-26 Ian Allister Ramshaw Recombinant chimeric vaccine
DE69034078T2 (de) * 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
WO1990013640A1 (en) * 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines

Also Published As

Publication number Publication date
AU2790292A (en) 1993-04-27
DE69230993T3 (de) 2004-12-16
DE69230993D1 (de) 2000-06-08
EP0559884B1 (fr) 2000-05-03
WO1993006223A1 (fr) 1993-04-01
JPH06502771A (ja) 1994-03-31
ES2147553T5 (es) 2004-11-16
AU666142B2 (en) 1996-02-01
CA2097185C (fr) 2007-07-24
CA2097185A1 (fr) 1993-03-28
SG49081A1 (en) 1998-05-18
EP0559884A1 (fr) 1993-09-15
ATE192500T1 (de) 2000-05-15
DE69230993T2 (de) 2000-11-30
FR2681786B1 (enExample) 1995-05-12
JP3487597B2 (ja) 2004-01-19
FR2681786A1 (fr) 1993-04-02
ES2147553T3 (es) 2000-09-16
DK0559884T3 (da) 2000-10-02
EP0559884B2 (fr) 2004-04-07
GR3034094T3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE3684892D1 (de) Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens.
ES8505724A1 (es) Procedimiento para la produccion de polipetidos mediante levadura.
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
BR9712348A (pt) molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração.
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
DK0811068T3 (da) Humane DNase I varianter
ATE278011T1 (de) Human dnase ii
DE69306273D1 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
EP0218432A3 (en) Methods for cdna cloning, and vector-primer dna, plasmid dna and linker dna, used in the said methods
AR242636A1 (es) Gen con codificacion para actividad de factor estimulante de colonias de granulocitos humanos.
MX9706429A (es) Variantes de dnasa i humana.